

Polyzois Makras

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3942743/polyzois-makras-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

2,329
citations

24
h-index

45
g-index

118
ext. papers

2,907
ext. citations

4.4
avg, IF

5.42
L-index

#	Paper	IF	Citations
110	Prevalence of the mutation in Greek adults with Langerhans cell histiocytosis.. <i>Pediatric Hematology and Oncology</i> , 2022 , 1-9	1.7	0
109	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. <i>Bone</i> , 2022 , 158, 116354	4.7	0
108	Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. <i>Bone</i> , 2022 , 154, 116209	4.7	0
107	Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.. <i>Blood</i> , 2022 ,	2.2	2
106	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021 , 13,	6.6	3
105	Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. <i>Endocrine</i> , 2021 , 73, 223-225	4	0
104	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. <i>Maturitas</i> , 2021 , 147, 19-25	5	6
103	̢sin levels in postmenopausal women with an incident hip fracture. <i>Endocrine</i> , 2021 , 73, 719-722	4	0
102	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4155-e4162	5.6	6
101	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , 2021 , 24, 338-340	3.5	3
100	Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas. <i>JBMR Plus</i> , 2021 , 5, e10431	3.9	1
99	Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	24
98	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. <i>Calcified Tissue International</i> , 2021 , 108, 587-594	3.9	5
97	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. <i>Journal of Clinical Densitometry</i> , 2021 , 24, 591-596	3.5	3
96	Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. <i>Bone Reports</i> , 2021 , 15, 101128	2.6	2
95	Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. <i>Bone Reports</i> , 2020 , 12, 100267	2.6	14
94	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	6

93	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , 2020 , 138, 115478	4.7	13
92	OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
91	The annual incidence of Langerhans cell histiocytosis among adults living in Greece. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28422	3	7
90	Combination and sequential treatment in women with postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 477-490	4	18
89	SUN-LB65 Circulating Micrnas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
88	Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2020 , 69, 516-518	4.1	3
87	Extra-skeletal effects of bisphosphonates. <i>Metabolism: Clinical and Experimental</i> , 2020 , 110, 154264	12.7	9
86	Experience gained from the implementation of the fracture liaison service in Greece. <i>Archives of Osteoporosis</i> , 2020 , 15, 12	2.9	1
85	Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the "ACROSS" study. <i>Archives of Osteoporosis</i> , 2020 , 15, 163	2.9	0
84	Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder. <i>Biomedicines</i> , 2020 , 8,	4.8	3
83	Gender Predilection in Sporadic Parathyroid Adenomas. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
82	Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. <i>Hormones</i> , 2020 , 19, 581-591	3.1	0
81	Off-label uses of denosumab in metabolic bone diseases. <i>Bone</i> , 2019 , 129, 115048	4.7	20
80	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. <i>Metabolism: Clinical and Experimental</i> , 2019 , 93, 100-102	12.7	8
79	Bazedoxifene for the treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1201-1210	10	15
78	The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece. <i>Archives of Osteoporosis</i> , 2019 , 14, 39	2.9	10
77	Hypoparathyroidism: is it that easy to treat?. <i>Hormones</i> , 2019 , 18, 55-63	3.1	0
76	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 2220-2228	6.3	64

75	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , 2019 , 127, 401-418	4.7	16
74	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019 , 19, 253-257	1.3	
73	Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019 , 19, 379-384	1.3	2
72	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. <i>Hormones</i> , 2019 , 18, 65-70	3.1	11
71	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , 2019 , 120, 44-49	4.7	13
70	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. <i>Calcified Tissue International</i> , 2018 , 103, 107-108	3.9	5
69	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. <i>European Journal of Endocrinology</i> , 2018 , 179, R31-R45	6.5	63
68	Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1206-1213	5.6	39
67	Bone disease in primary hyperparathyroidism. <i>Metabolism: Clinical and Experimental</i> , 2018 , 80, 57-65	12.7	28
66	Irisin in metabolic diseases. <i>Endocrine</i> , 2018 , 59, 260-274	4	109
65	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , 2018 , 17, 573-579	3.1	3
64	Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek population. <i>Archives of Osteoporosis</i> , 2018 , 13, 111	2.9	13
63	Bone metabolism in Langerhans cell histiocytosis. <i>Endocrine Connections</i> , 2018 , 7, R246-R253	3.5	5
62	Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. <i>Metabolism: Clinical and Experimental</i> , 2017 , 69, 107-111	12.7	10
61	Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1291-1296	6.3	197
60	Bisphosphonates or denosumab discontinuation and risk of fractures. <i>Maturitas</i> , 2017 , 102, 75	5	4
59	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 198-201	12.7	1
58	Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. <i>European Journal of Endocrinology</i> , 2017 , 176, 677-683	6.5	54

57	Evaluation of the first fracture liaison service in the Greek healthcare setting. <i>Archives of Osteoporosis</i> , 2017 , 12, 3	2.9	5
56	Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1137-1144	5.9	11
55	Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. <i>European Journal of Endocrinology</i> , 2017 , 176, 169-176	6.5	67
54	Periostin and sclerostin levels in juvenile Paget's disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017 , 14, 269-271		1
53	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016 , 34, 447-56	2.9	13
52	Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, L89-90	5.6	
51	Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016033	3.2	15
50	Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians' criteria in the choice of treatment. <i>Hormones</i> , 2016 , 15, 413-422	3.1	
49	Novel therapies for osteoporosis. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, 1199-214	12.7	54
48	Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, 1291-7	12.7	21
47	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 145-57	5.9	13
46	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 299-306	6.4	9
45	Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E282-6	5.6	6
44	Bisphosphonate Therapy in Langerhans Cell Histiocytosis: An International Retrospective Descriptive Study. <i>Blood</i> , 2015 , 126, 2209-2209	2.2	1
43	Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. <i>Hormone and Metabolic Research</i> , 2014 , 46, 145-9	3.1	22
42	Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. <i>Osteoporosis International</i> , 2013 , 24, 2127-32	5.3	11
41	Incidence of hip fractures in Greece during a 30-year period: 1977-2007. <i>Osteoporosis International</i> , 2013 , 24, 1579-85	5.3	23
40	Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naïve postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3206-12	5.6	42

39	Coexistence of Graves disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 1350-6	12.7	15
38	Cladribine therapy in adults with advanced Langerhans cell histiocytosis. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1541-3	1.9	6
37	Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 72	4.2	195
36	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 2013 , 79, 499-503	3.4	37
35	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , 2012 , 50, 1130-4	4.7	24
34	The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. <i>Clinical Endocrinology</i> , 2012 , 77, 816-22	3.4	4
33	Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans cell histiocytosis. <i>Pituitary</i> , 2012 , 15 Suppl 1, S28-32	4.3	2
32	Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature. <i>Hormones</i> , 2012 , 11, 419-27	3.1	6
31	Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2012 , 58, 819-22	3	10
30	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. <i>Therapeutics and Clinical Risk Management</i> , 2012 , 8, 295-306	2.9	54
29	Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. <i>Molecular Therapy</i> , 2012 , 20, 6-7	11.7	10
28	Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E618-21	5.6	7
27	Performance of the mini nutritional assessment score in the detection of vitamin D status in an elderly Greek population. <i>Hormone and Metabolic Research</i> , 2012 , 44, 896-9	3.1	8
26	Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis. <i>Medical Hypotheses</i> , 2011 , 77, 109-11	3.8	3
25	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. <i>Hormones</i> , 2011 , 10, 174-95	3.1	22
24	Skeletal implications of isolated bone marrow mastocytosis. <i>Haematologica</i> , 2011 , 96, e27; author reply e28	6.6	0
23	No effect of rosuvastatin in the zoledronate-induced acute-phase response. <i>Calcified Tissue International</i> , 2011 , 88, 402-8	3.9	15
22	Paget disease of bone and calcium homeostasis: focus on bisphosphonate treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011 , 119, 519-24	2.3	15

21	A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels. <i>Gynecological Endocrinology</i> , 2011 , 27, 384-90	2.4	7
20	Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 60-4	5.6	45
19	Medical treatment of hypercalcaemia. <i>Hormones</i> , 2009 , 8, 83-95	3.1	23
18	High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. <i>Clinical Endocrinology</i> , 2009 , 71, 772-8	3.4	62
17	Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. <i>Bone</i> , 2009 , 44, 766-71	4.7	7
16	Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1386-9	5.6	14
15	Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, 514-23		30
14	Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008 , 101, 31-40	2.7	14
13	Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. <i>Clinical Endocrinology</i> , 2007 , 67, 917-22	3.4	53
12	Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 1154-9	2.2	11
11	Endocrine manifestations in Langerhans cell histiocytosis. <i>Trends in Endocrinology and Metabolism</i> , 2007 , 18, 252-7	8.8	82
10	Systemic and endocrine manifestations of Langerhans cell histiocytosis: current concepts in diagnosis and management. <i>Expert Review of Endocrinology and Metabolism</i> , 2007 , 2, 773-783	4.1	4
9	Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH). <i>Neuroradiology</i> , 2006 , 48, 37-44	3.2	48
8	The diagnosis and differential diagnosis of endogenous Cushing's syndrome. <i>Hormones</i> , 2006 , 5, 231-50	3.1	18
7	Effect of 4 weeks of basic military training on peripheral blood leucocytes and urinary excretion of catecholamines and cortisol. <i>Journal of Sports Sciences</i> , 2005 , 23, 825-34	3.6	25
6	Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH). <i>Pituitary</i> , 2005 , 8, 169-74	4.3	18
5	Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. <i>Endocrine-Related Cancer</i> , 2005 , 12, 683-99	5.7	101
4	Langerhans cell histiocytosis in an adult patient manifested as recurrent skull lesions and Diabetes Insipidus. <i>Hormones</i> , 2004 , 3, 59-64	3.1	3

3	Growth without growth hormone (GH): a case report. <i>Hormones</i> , 2004 , 3, 259-65	3.1	3
2	GH deficiency in adults. <i>Hormones</i> , 2003 , 2, 217-8	3.1	4
1	Outbreak of meningococcal disease after an influenza B epidemic at a Hellenic Air Force recruit training center. <i>Clinical Infectious Diseases</i> , 2001 , 33, e48-50	11.6	21